Letters from a Pharmacist
Subscribe
Sign in
Home
Notes
Drug Trials
Pharmacotherapy Pearls
Scientific Methods
Archive
About
Latest
Top
Discussions
OASIS-4 Trial
Phase 3 trial comparing oral semaglutide 25mg or placebo daily in persons who are overweight or obese, without diabetes.
Sep 21
2
Bias in RCTs - part 2 [blinding / masking]
What is seen can bias; what is blinded protects.
Sep 9
•
J Gamble, PhD RPh
3
SGLT2 Inhibitor Pearls
Clinical highlights for the ‘flozins’.
Sep 2
•
J Gamble, PhD RPh
7
August 2025
What are the top 5 most dangerous drug-drug interactions in primary care?
Drug-drug interactions are common but not all equal.
Aug 26
•
J Gamble, PhD RPh
5
Bias in RCTs - part 1
Randomization isn’t enough ... the list must be hidden.
Aug 19
•
J Gamble, PhD RPh
3
Types of Randomization: A Short Primer
From simple to blocked to adaptive
Aug 19
•
J Gamble, PhD RPh
1
SURMOUNT-5 Trial
A head to head trial between tirzepatide and semaglutide for the treatment of obesity
Aug 12
•
J Gamble, PhD RPh
1
Drug Therapy Problems: An upcoming 7-part series
Twice a month Letters from a Pharmacist will post a case vignette for the community to vote on their treatment recommendations.
Aug 5
•
J Gamble, PhD RPh
2
July 2025
DPP4 Inhibitor Pharmacotherapy Pearls
Dipeptidyl peptidase inhibitors, otherwise known as DPP4 inhibitors are a commonly used glucose-lowering medication for the management of type 2…
Jul 29
•
J Gamble, PhD RPh
2
The Rule of 3 in critical appraisal
A useful conservative estimate of the upper plausible rate of an event
Jul 15
•
J Gamble, PhD RPh
2
Fixed ratio combinations of a GLP-1 receptor agonist and a basal insulin: 7 pearls
Convenience, slow titration of GLP1RA, simple dose adjustments
Jul 8
•
J Gamble, PhD RPh
2
Thank you to the first 100 subscribers to Letters from a Pharmacist!
Letters from a Pharmacist subscriber poll
Jul 2
•
J Gamble, PhD RPh
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
